Form 4: SOLENO CBO Kevin Norrett Granted Equity Awards

Soleno Therapeutics' Chief Business Officer, Kevin Norrett, was granted 14,286 restricted stock units and 64,286 employee stock options, aligning executive incentives with future company performance.

Summary

• Kevin Norrett, Chief Business Officer of Soleno Therapeutics Inc. (SLNO), was granted equity awards.
• The awards include 14,286 restricted stock units (RSUs) and 64,286 employee stock options.
• The RSUs represent a contingent right to receive one share of Common Stock each, with 50% vesting on November 17, 2026, and one-third of the remaining RSUs vesting each one-year anniversary thereafter.
• The employee stock options have an exercise price of $47.25 per share and an expiration date of November 17, 2035.
• One-fourth of the shares subject to the option will vest on November 17, 2026, with one forty-eighth vesting each month thereafter.
• All vesting is contingent upon Mr. Norrett's continued service as a Service Provider.
• Following these transactions, Mr. Norrett beneficially owns 14,286 shares of Common Stock (RSUs) and 64,286 employee stock options.

Sentiment

Score: 7

Explanation: The granting of equity awards to a key executive is generally a positive signal, indicating management alignment with long-term company performance and retention of talent. It's a standard compensation practice.

Positives

• The granting of equity awards to the Chief Business Officer aligns management's interests with long-term shareholder value.
• The awards incentivize continued service and performance through multi-year vesting schedules, promoting executive retention.

Future Outlook

The equity grants with multi-year vesting schedules indicate an expectation of continued service from the Chief Business Officer and a focus on long-term company performance.

Industry Context

Equity grants, including restricted stock units and stock options, are standard compensation practices in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives, aligning their interests with the company's long-term success and shareholder value creation.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term company performance.
• Employees: Standard executive compensation practices can signal stability and a structured approach to talent management.

Next Steps

• Vesting of 50% of RSUs on November 17, 2026.
• Vesting of one-third of remaining RSUs each one-year anniversary thereafter.
• Vesting of one-fourth of employee stock options on November 17, 2026.
• Monthly vesting of one forty-eighth of employee stock options thereafter.

Key Dates

Recommendation

The filing reports standard executive equity compensation, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests. It does not provide new fundamental information about the company's operations or financial performance that would warrant a change in investment thesis, hence a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Soleno Therapeutics, SLNO, Kevin Norrett, Chief Business Officer, CBO, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Executive Compensation, Insider Transaction, Form 4